CNS Pharmaceuticals (CNSP) Stock Overview

A clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. More details

CNSP fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($6M)

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months compared to the US market

+ 1 more risk

CNSP Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

CNS Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for CNS Pharmaceuticals
Historical stock prices
Current Share Price	US$6.76
52 Week High	US$34.80
52 Week Low	US$1.90
Beta	0.54
1 Month Change	210.09%
3 Month Change	65.28%
1 Year Change	-53.44%
3 Year Change	-99.90%
5 Year Change	-99.90%
Change since IPO	-99.90%

Recent updates

Seeking Alpha • Aug 15

CNS Pharmaceuticals reports Q2 results

CNS Pharmaceuticals press release (NASDAQ:CNSP): Q2 Net Loss of $3.6M As of June 30, 2022, the company had cash of approximately $9M and working capital of approximately $10.5M. The company's current expectation is that the cash on hand and the proceeds from the offering during January is sufficient to fund our operations into 2023.

Analysis Article • Dec 04

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Shareholder Returns

	CNSP	US Pharmaceuticals	US Market
7D	-13.8%	-1.5%	2.6%
1Y	-53.4%	30.4%	26.2%

Return vs Industry: CNSP underperformed the US Pharmaceuticals industry which returned 33.5% over the past year.

Return vs Market: CNSP underperformed the US Market which returned 31.1% over the past year.

Price Volatility

Is CNSP's price volatile compared to industry and market?
CNSP volatility
CNSP Average Weekly Movement	69.7%
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.1%
10% least volatile stocks in US Market	3.2%

Stable Share Price: CNSP's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CNSP's weekly volatility has increased from 36% to 70% over the past year.

About the Company

Founded	Employees	CEO	Website
2017	5	Rami Levin	cnspharma.com

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.

CNS Pharmaceuticals, Inc. Fundamentals Summary

How do CNS Pharmaceuticals's earnings and revenue compare to its market cap?
CNSP fundamental statistics
Market cap	US$5.92m
Earnings (TTM)	-US$15.85m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.3x

P/E Ratio

Is CNSP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CNSP income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$15.85m
Earnings	-US$15.85m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-19.53
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	7.3%

How did CNSP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/11 12:36
End of Day Share Price	2026/05/11 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CNS Pharmaceuticals, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Bruce Jackson	Benchmark Company
Robert LeBoyer	Ladenburg Thalmann & Company
Jason McCarthy	Maxim Group

CNS Pharmaceuticals (CNSP) Stock Overview

Risk Analysis

CNS Pharmaceuticals, Inc. Competitors

Clearmind Medicine

RedHill Biopharma

China SXT Pharmaceuticals

Pulmatrix

Price History & Performance

Recent News & Updates

CNS Pharmaceuticals, Inc. announced that it expects to receive $22.515858 million in funding from ADAR1 Capital Management, LLC, Ikarian Capital, LLC, Stonepine Capital Management LLC, Nazare Partners

New major risk - Share price stability

New minor risk - Share price stability

High number of new and inexperienced directors

CNS Pharmaceuticals, Inc., Annual General Meeting, Nov 17, 2025

New major risk - Financial position

Recent updates

CNS Pharmaceuticals, Inc. announced that it expects to receive $22.515858 million in funding from ADAR1 Capital Management, LLC, Ikarian Capital, LLC, Stonepine Capital Management LLC, Nazare Partners

New major risk - Share price stability

New minor risk - Share price stability

High number of new and inexperienced directors

CNS Pharmaceuticals, Inc., Annual General Meeting, Nov 17, 2025

New major risk - Financial position

CNS Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.996373 million.

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $14 million.

New major risk - Financial position

No longer forecast to breakeven

New minor risk - Profitability

New major risk - Revenue and earnings growth

New major risk - Share price stability

Forecast to breakeven in 2027

CNS Pharmaceuticals Receives Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3 million.

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals, Inc. announced that it expects to receive funding from Cortice Biosciences Incorporated

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.2 million.

The Nasdaq Hearings Panel Grants the Requested Extension to CNS Pharmaceuticals Until August 12, 2024

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million.

CNS Pharmaceuticals, Inc. announced a financing transaction

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3725 million.

New major risk - Share price stability

CNS Pharmaceuticals, Inc., Annual General Meeting, Apr 30, 2024

CNS Pharmaceuticals Receives Non-Compliance Letter Form Nasdaq

CNS Pharmaceuticals Provides Non-Compliance Update

CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

New major risk - Negative shareholders equity

CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland

Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (Gbm)

CNS Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement Pursuant to Nasdaq’s Listing Rule 5550(b)(1)

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

CNS Pharmaceuticals, Inc. Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme

Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors

CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Investigator-Initiated Phase 1B/2 Trial to Be Conducted At the Pomeranian Medical University in Poland

Cns Pharmaceuticals, Inc. Appoints Faith Charles as Independent Member and as Chairperson of the Board of Directors

CNS Pharmaceuticals, Inc Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

CNS Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Insufficient new directors

CNS Pharmaceuticals, Inc. Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Provides A Clinical Update of Its Anti-Cancer Drug Candidates Currently in Development for the Treatment of Primary and Metastatic Brain and CNS Cancer

CNS Pharmaceuticals reports Q2 results

CNS Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2022

CNS Pharmaceuticals Inc. Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Price target increased to US$10.00

Insufficient new directors

CNS Pharmaceuticals, Inc. Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

CNS Pharmaceuticals, Inc. announced that it expects to receive $11.500001 million in funding

Insufficient new directors

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

CNS Pharmaceuticals, Inc. Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

Shareholder Returns

Price Volatility

About the Company

CNS Pharmaceuticals, Inc. Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status